Wells Fargo raised the firm’s price target on Incyte (INCY) to $70 from $68 and keeps an Equal Weight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte initiated with a Neutral at UBS
- Incyte says Phase 3 inMIND trial met primary endpoint of PFS
- Incyte announces results from Phase 3 trial evaluating retifanlimab in NSCLC
- Incyte gets FDA orphan designation for treatment of nodal marginal zone lymphoma
- Biotech Alert: Searches spiking for these stocks today
Questions or Comments about the article? Write to editor@tipranks.com